Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Jun 25, 2030 · High confidence
20-year base term ends Jun 25, 2030
Jun 25, 2010
Jun 25, 2030
Nov 3, 2020
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 25, 2010, when application PCT/US2010/040082, the earliest non-provisional in its chain, was filed (this one was filed Nov 19, 2018) | Jun 25, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,139,399, US 9,377,454) | resolves to Jun 25, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 25, 2030 | High confidence |
Partial family
| Application PCT/US2010/004008 | PCT application no patent term | no patent term |
| Application PCT/US2010/040082 | PCT application no patent term | no patent term |
| US 9,377,454 | In force Jun 2030 | Jun 2030 |
| Application 15/165,318 | Abandoned not computed | not computed |
| US 10,139,399 | In force Jun 2030 | Jun 2030 |
| US 10,823,727 | this patent Jun 2030 | Jun 2030 |
| US 11,639,927 | In force Jun 2030 | Jun 2030 |
| US 11,598,767 | In force Jun 2030 | Jun 2030 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 15, 2021 Reel 55659, frame 430 | Horizon Orphan LLC; Horizon Therapeutics USA, Inc.; Viela Bio, Inc. | Citibank, N.a. | Security Agreement |
| May 27, 2021 Reel 56369, frame 172 | Rosario-jansen, Theresa; Wright, David Erick | Savient Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| May 27, 2021 Reel 56408, frame 201 | Savient Pharmaceuticals, Inc. | Crealta Pharmaceuticals LLC | Assignment of Assignor's Interest |
| May 27, 2021 Reel 56408, frame 238 | Crealta Pharmaceuticals LLC | Horizon Pharma USA Rheumatology LLC | Change of Name |
| May 27, 2021 Reel 56408, frame 241 | Horizon Pharma USA Rheumatology LLC | Horizon Pharma Rheumatology LLC | Change of Name |
| Oct 31, 2022 Reel 61805, frame 76 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Assignment of Assignor's Interest |
| Dec 1, 2022 Reel 62073, frame 930 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 061805 Frame 0076. Assignor(S) Hereby Confirms the Assignment. |
| Oct 6, 2023 Reel 65154, frame 64 | Citibank, N.a. | Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC); Horizon Therapeutics USA, Inc.; Viela Bio, Inc. | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Horizon Therapeutics U.S. Holding LLC (FKA Horizon Orphan LLC) | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Horizon Therapeutics USA, Inc. | Release of Security Interest |
| Oct 6, 2023 reel/frame not recorded | Citibank, N.a. | Viela Bio, Inc. | Release of Security Interest |
| Nov 6, 2026 Reel 76662, frame 840 | Horizon Therapeutics USA, Inc. | Horizon Therapeutics Ireland Dac | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 10,139,399, US 9,377,454, ends no earlier than this term, so it caps nothing.